

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): March 12, 2012

Enzo Biochem, Inc.

(Exact Name of Registrant as Specified in Its Charter)

New York

(State or Other Jurisdiction of Incorporation)

001-09974

(Commission File Number)

13-2866202

(IRS Employer Identification No.)

**527 Madison Avenue
New York, New York**

(Address of Principal Executive Offices)

10022

(Zip Code)

(212) 583-0100

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02. Results of Operations and Financial Condition.

On March 12, 2012, Enzo Biochem, Inc., a New York corporation, (the “Company”) issued a press release announcing its operating results for its second fiscal quarter ended January 31, 2012.

A copy of the press release is furnished as Exhibit 99.1 attached hereto and is incorporated by reference in its entirety into this item 2.02 of this Current Report on Form 8-K.

In accordance with General Instruction B.2. of Form 8-K, the information contained in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such information shall not be incorporated by reference in any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as otherwise expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure.

The information provided in Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference in its entirety.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of Enzo Biochem, Inc., dated March 12, 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: March 14, 2012

By: /s/ Barry Weiner
Barry Weiner
President, Chief Financial Officer,
Principal Accounting Officer and Director

EXHIBIT INDEX

Exhibit No.

Description

99.1

Press Release of Enzo Biochem, Inc., dated March 12, 2012



*news
release*

Enzo Biochem, Inc.
527 Madison Avenue
New York, NY 10022

FOR IMMEDIATE RELEASE

ENZO BIOCHEM REPORTS IMPROVED SECOND QUARTER RESULTS

NEW YORK, NY, March 12, 2012 – [Enzo Biochem Inc.](#) (NYSE:ENZ) today reported improved results for the fiscal quarter ended January 31, 2012. Among the quarter’s highlights:

- **Total revenues increased 5% year over year, led by strong organic growth at Enzo Clinical Labs and increased royalty and licensee income;**
- **Gross margin was up 12%;**
- **Operating results improved by \$1.5 million;**
- **Approval received by New York State Department of Health for ColonSentry, a proprietary assay for assessment of a patient’s risk of having colorectal cancer;**
- **AmpiProbe™ HCV Assay, first of Company’s proprietary nucleic acid amplification technology, to be unveiled at leading European medical meeting.**

“The quarter was another period of progress, both on the operational and development fronts. Enzo Clinical Labs posted another quarter of strong organic growth. At Enzo Life Sciences margins have begun improving as our efforts to streamline the product mix, improve marketing and enhance manufacturing start to yield results. Our recent announcements related to molecular diagnostics further support our progress in the development of novel assays that hold promise to contribute to the advancement of healthcare,” said Barry Weiner, President.

Second Quarter Results

Revenues for the second fiscal quarter were \$25.0 million, compared with \$23.7 million a year ago, an increase of 5%, as a result of both continued growth at Enzo Clinical Labs and an increase in royalty and licensing fee income. Gross profit improved to 46%, from 44% year over year. Operating expenses declined \$0.5 million to \$15.4 million, due to a reduction in legal and R&D expenses, partially offset by an increased provision for uncollectible accounts receivable due to higher service volume at Enzo Clinical Labs. However, the Company increased its developmental effort in the area of new molecular tests and technology platform development. Selling, general and administrative expenses as a percentage of revenues declined to 46% from 49% in the year ago period. The net loss for the period was reduced by \$1.5 million or (\$.04) per diluted share, declining to \$4.2 million or (\$.11) loss per diluted share. EBITDA loss

was lower by \$1.4 million or 32% to \$3.0 million. Total cash used was \$2.8 million, which included a non-recurring cash payment of \$1.1 million for the final earn-out from a previous acquisition and cash used in operations of \$1.3 million.

As of January 31, 2012, cash, cash equivalents and short term investments totaled \$18.6 million. Working capital amounted to \$26.7 million. There was no long-term debt.

Segment Quarterly Results

Enzo Clinical Labs increased revenues organically by \$1.8 million or 15%, as the Lab continued to expand marketing, reaching more physicians and increasing specimen volume. Gross margin was up 13%, to \$5.4 million, however higher costs impacted the gross profit percentage by 100 basis points. Increases in SG&A from staff additions and higher commission levels were both driven from the higher service volume. The increase in provision for uncollectible accounts receivables was due to greater patient service volume, although as a percentage of revenue the provision was comparable in both periods at 8%.

At Enzo Life Sciences, operating income rose, as a result of a reduction in expenses and improved operations. Revenues amounted to \$9.5 million as compared to \$10.2 million, due largely to the continued softness in the academic market and certain distributed products. The Company continues to achieve benefits from its program to integrate the previously acquired global businesses, and focus on greater efficiencies in manufacturing, which drove improved gross profit as a percentage of revenues. Royalty and license fee income improved 7% to \$1.3 million. Operating income improved by \$1.1 million to \$0.7 million, compared to a year ago operating loss of \$0.4 million.

Year-to –Date Highlights

Year to date revenues advanced by \$1.3 million or 3% to \$50.7 million. Enzo Clinical Labs' revenues experienced 15% organic growth while Enzo Life Sciences' product revenues declined 6% and royalty and licensing revenues declined \$1.1 million, largely due to previously reported reduced first quarter royalty and license fees. Gross margins were \$23.4 million, 2% lower than a year ago also impacted by royalty and licensing fees. Operating expenses, including R&D, SG&A, legal and provision for uncollectible accounts, increased by 4%, with higher selling costs and provision for uncollectible accounts receivables attributed to increased service volume at Clinical Labs. The year-to-date loss amounted to \$8.7 million, compared to \$6.8 million in the corresponding year-ago period. Cash used in operations was \$3.6 million.

Other Developments

As reported previously, the New York State Department of Health has approved Enzo Clinical Labs' use of the ColonSentry™ test for providing an assessment of a patient's risk of having colorectal cancer. The information provided by this test can

guide physicians' recommendations to patients for a colonoscopy, which remains highly underutilized by many individuals.

On March 31, 2012, Enzo will make its first peer-reviewed presentation of its novel AmpProbe™ technology platform at the annual meeting in London of the prestigious European Society of Clinical Microbiology and Infectious Diseases (ESCMID). The platform can provide for the development of low cost high sensitivity, real time nucleic acid amplification assays. Initially, the plan is to seek CE-IVD (*Conformité Européenne in vitro diagnostic*) designation for AmpProbe™ HCV the first assay based on this platform, which would allow marketing of this product as a diagnostic throughout the European Union. Application for approval by the New York State Department of Health as a laboratory developed test is also planned.

Conference Call

The Company will conduct a conference call on March 13, 2012 at 8:30 AM ET. The call can be accessed by dialing 1-888-459-5609. International callers can dial 1-973-321-1024. Please reference PIN number 59249560. Interested parties may also listen over the Internet at <http://phoenix.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=94391&eventID=4734348>. To listen to the live call on the Internet, please go to the web site at least fifteen minutes early to register, download and install any necessary audio software. For those who cannot listen to the live broadcast, a replay will be available approximately two hours after the end of the live call, through midnight (ET) on March 27, 2012. The replay of the conference call can be accessed by dialing 1-800-585-8367, and when prompted, use PIN number 59249560. International callers can dial 1-404-537-3406, using the same PIN number.

NON-GAAP Financial Measures

To comply with Regulation G promulgated pursuant to the Sarbanes-Oxley Act, Enzo Biochem attached to this news release and will post to the Company's investor relations web site (www.enzo.com) any reconciliation of differences between non-GAAP financial information that may be required in connection with issuing the Company's quarterly financial results.

The Company uses EBITDA, as a measure of performance to demonstrate earnings exclusive of interest, taxes, depreciation and amortization. The Company manages its business based on its operating cash flows. The Company, in its daily management of its business affairs and analysis of its monthly, quarterly and annual performance, makes its decisions based on cash flows, not on the amortization of assets obtained through historical activities. The Company, in managing its current and future affairs, cannot affect the amortization of the intangible assets to any material degree, and therefore uses EBITDA as its primary management guide. Since an outside investor may base its evaluation of the Company's performance based on the Company's net loss not its cash flows, there is a limitation to the EBITDA measurement. EBITDA is not, and should not be considered, an alternative to net loss, loss from operations, or any other measure for determining operating performance of liquidity, as determined under accounting principles generally accepted in the United States (GAAP). The most directly comparable GAAP reference in the Company's case is the removal of interest, taxes, depreciation and amortization.

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and rapidly deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company's Form 10-K for the fiscal year ended July 31, 2011. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

###

Contact:

For Enzo Biochem, Inc.

Steven Anreder

Anreder & Company

212-532-3232

steven.anreder@anreder.com

Michael Wachs

CEOcast, Inc.

212-732-4300

or mwachs@ceocast.com

ENZO BIOCHEM, INC.
(in thousands, except per share data)

Selected operations data:

	Three months ended		Six months ended	
	January 31,		January 31,	
	(unaudited)		(unaudited)	
	2012	2011	2012	2011
Clinical laboratory services	\$14,123	\$12,278	\$28,310	\$24,668
Product revenues	9,542	10,237	19,245	20,421
Royalty and license fee income	1,308	1,219	3,170	4,297
Total revenues	<u>24,973</u>	<u>23,734</u>	<u>50,725</u>	<u>49,386</u>
Gross profit	<u>11,579</u>	<u>\$10,331</u>	<u>23,380</u>	<u>23,805</u>
Loss before income tax provision	(\$4,076)	(\$5,562)	(\$8,402)	(\$6,621)
Provision for income taxes (A)	(145)	(146)	(313)	(212)
Net loss	<u>(\$4,221)</u>	<u>(\$5,708)</u>	<u>(\$8,715)</u>	<u>(\$6,833)</u>
Basic and diluted loss per share	<u>(\$0.11)</u>	<u>(\$0.15)</u>	<u>(\$0.23)</u>	<u>(\$0.18)</u>
Weighted average shares outstanding - basic and diluted	<u>38,616</u>	<u>38,198</u>	<u>38,607</u>	<u>38,179</u>
<u>Reconciliation of GAAP Net Loss to EBITDA</u>				
Net loss	(\$4,221)	(\$5,708)	(\$8,715)	(\$6,833)
Depreciation and amortization	1,045	1,099	2,259	2,162
Interest income	(14)	(4)	(12)	(9)
Provision for income taxes	145	146	313	212
EBITDA (B)	<u>(\$3,045)</u>	<u>(\$4,467)</u>	<u>(\$6,155)</u>	<u>(\$4,468)</u>

Notes:

A- All periods reflect effective tax rates below the statutory rate due to inability to recognize future tax benefits.

B- EBITDA is a non-GAAP measure, as described in the attached press release

Selected balance sheet data:

	<u>January 31, 2012</u>	<u>July 31, 2011</u>
Cash and cash equivalents and short term investments	\$18,589	\$24,161
Working capital	\$26,678	\$33,670
Stockholders' equity	\$78,841	\$88,715
Total assets	\$98,758	\$109,474